Fluticasone/salmeterol is associated with a higher risk of pneumonia and pneumonia related events in comparison with budesonide/formoterol in patients with COPD Combination treatment with inhaled corticosteroids and long acting β 2 agonists decrease exacerbations and improve quality of life in patients with chronic obstructive pulmonary disease (COPD) however; a potential concern is an increased risk of pneumonia. Although previous studies have shown the risk of pneumonia to increase with fluticasone/salmeterol versus placebo and tiotropium, there has been no direct comparison of fixed combinations of inhaled corticosteroid/long acting β 2 agonists.
